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Abstract
Background: In Kenya, the comparative incidences of tuberculosis among persons with and without HIV have not been
described, and the differential impact of public health interventions on tuberculosis incidence in the two groups is
unknown.
Methods: We estimated annual tuberculosis incidence stratified by HIV status during 2006–2012 based on the numbers of
reported tuberculosis patients with and without HIV infection, the prevalence of HIV infection in the general population,
and the total population. We also made crude estimates of annual tuberculosis incidence stratified by HIV status during
1998–2012 by assuming a constant ratio of HIV prevalence among tuberculosis patients compared to the general
population.
Results: Tuberculosis incidence among both adults with HIV and adults without HIV increased during 1998–2004 then
remained relatively stable until 2007. During 2007–2012, tuberculosis incidence declined by 28–44% among adults with HIV
and by 11–26% among adults without HIV, concurrent with an increase in antiretroviral therapy uptake. In 2012,
tuberculosis incidence among adults with HIV (1,839–1,936 cases/100,000 population) was still eight times as high as among
adults without HIV (231–238 cases/100,000 population), and approximately one third of tuberculosis cases were attributable
to HIV.
Conclusions: Although tuberculosis incidence has declined among adults with and without HIV, the persistent high
incidence of tuberculosis among those with HIV and the disparity between the two groups are concerning. Early diagnosis
of HIV, early initiation of antiretroviral therapy, regular screening for tuberculosis, and isoniazid preventive therapy among
persons with HIV, as well as tuberculosis control in the general population, are required to address these issues.
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Introduction
Despite declining incidence in recent years, tuberculosis remains
a leading cause of death among infectious diseases globally, second
only to HIV [1]. In addition, the concurrent global tuberculosis
and HIV epidemics interact synergistically, with HIV increasing
tuberculosis incidence and tuberculosis being associated with both
mortality and incidence of other AIDS-defining illnesses among
persons living with HIV [2].
HIV is an important driver of the tuberculosis epidemic in
Kenya, which is classified as a high-burden country for both
tuberculosis and HIV. In 2012, 39% of all reported tuberculosis
cases in Kenya occurred in persons living with HIV [1]. Studies
from Kenya have reported HIV infection to be associated with
default during tuberculosis treatment [3] and increased mortality
in tuberculosis patients [4]. However, while HIV test results for
newly diagnosed tuberculosis cases have been recorded in Kenya
since 2006, the comparative incidences of tuberculosis among
persons living with HIV and persons without HIV have not been
described. As a result, the differential impact of public health
interventions on tuberculosis incidence in the two groups is
unknown.
Provision of antiretroviral therapy and tuberculosis preventive
therapy to persons living with HIV have been shown to
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substantially reduce tuberculosis incidence in this population [5–
8]. In 2004, Kenya began a scale-up of antiretroviral therapy in
the public sector and started to integrate HIV testing and care into
the services provided for tuberculosis patients [9]. Current Kenyan
guidelines recommend that persons living with HIV be screened
for tuberculosis, and that those diagnosed with tuberculosis be
started on tuberculosis therapy. However, inadequate data exist to
determine the quality of this screening and diagnosis process. In
2011, only 65% of persons living with HIV who also had newly
diagnosed tuberculosis received treatment for both HIV and
tuberculosis [10]. Furthermore, tuberculosis preventive therapy
has not yet been widely implemented in Kenya [10].
Comparing tuberculosis incidence among persons with and
without HIV can uncover distinct trends in the epidemiology of
tuberculosis in these two populations [11] and can inform policy
on the specific interventions needed, as well as on the prioritization
of tuberculosis control and prevention efforts among persons living
with HIV. To help guide future programmatic interventions
aimed at reducing tuberculosis incidence and to gain insight into
the differential impact of existing interventions on people with and
without HIV, we estimated annual tuberculosis incidence stratified
by HIV status and annual population attributable fraction of
tuberculosis due to HIV.
Methods
Detailed Estimate of Tuberculosis Incidence Stratified by
HIV Status
We estimated annual tuberculosis incidence among adults living
with HIV and adults without HIV in Kenya during 2006–2012
based on the numbers of reported tuberculosis patients with and
without HIV infection, the prevalence of HIV infection in the
general population, and the total population. Because our data
source for prevalence of HIV infection was limited to adults aged
15–64 years, we focused our analysis on this age group. We
determined the population attributable fraction of tuberculosis
cases due to HIV by first calculating the difference between overall
tuberculosis incidence and estimated incidence of tuberculosis
among persons without HIV, then dividing this value by the
overall tuberculosis incidence.
We used data from the 2007 and 2012 Kenya AIDS Indicator
Surveys (KAIS) [12,13] to estimate prevalence of HIV infection
among adults aged 15–64 by year during 2006–2012. We assumed
a constant rate of change to estimate prevalence of HIV infection
during the years before and between surveys. We obtained
populations, by age, from the 1999 and 2009 Kenya censuses. We
estimated populations during years between and after the censuses
assuming a constant annual percentage growth in the total
population and applying proportions to estimate the population of
adults aged 15–64 years. For each year, we applied the estimated
prevalence of HIV infection to the estimated population of adults
to obtain populations of adults aged 15–64 with and without HIV
infection.
We obtained numbers of new tuberculosis cases reported each
year in adults during 2006–2012 from the Kenya Ministry of
Health Division of Leprosy, Tuberculosis and Lung Disease
(DLTLD). Because case counts were disaggregated only by
pediatric (age ,15 years) and adult (age $15 years) groups, we
were unable to exclude patients aged .64 years. We therefore
included all adult cases in our analysis and assumed them to all be
aged under 64 years. We also performed a sensitivity analysis in
which we instead assumed 95% of tuberculosis cases among adults
to have occurred in those aged 15–64 years, based on the age
distribution of adult tuberculosis patients in select provinces for
which disaggregated data were available. For each year, we
obtained the numbers of adult tuberculosis patients who had HIV
test results and the number with HIV-positive results.
We made upper-bound estimates for the total number of adult
tuberculosis patients with HIV by assuming the HIV prevalence in
patients without HIV test results to be the same as in patients with
HIV test results. We made lower-bound estimates by assuming the
prevalence of HIV infection in patients without HIV test results to
be the same as in the general adult population.
Trends in Antiretroviral Therapy Uptake
We obtained data on the numbers of adults in Kenya receiving
antiretroviral therapy, by year, from the National AIDS and STI
Control Program. We assumed that the number of adults aged .
64 years receiving antiretroviral therapy was negligible. We
calculated antiretroviral therapy uptake among adults (i.e., the
proportion of adults living with HIV who are receiving antiret-
roviral therapy) each year during 2006–2012 using the estimated
population of adults aged 15–64 living with HIV in Kenya
(method described above). This calculation of antiretroviral
Figure 1. New tuberculosis cases, by HIV test result – Kenya, 2006–2012. Total numbers of new tuberculosis cases (orange line), new
tuberculosis cases in patients with negative HIV test result (blue line), new tuberculosis cases in patients with positive HIV test result (red line), and
new tuberculosis cases in patients with unknown HIV test result (green line).
doi:10.1371/journal.pone.0099880.g001
Tuberculosis Trends by HIV Status, Kenya 1998–2012
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therapy uptake reflects the overall proportion of people living with
HIV on therapy, and does not describe uptake according to
national guidelines, nor the effect of changes in guidelines over the
study period.
Crude Estimate of Tuberculosis Incidence Stratified by
HIV Status
To evaluate trends over a longer time period than the years for
which availability of HIV test results for tuberculosis patients
would allow, we obtained number of adult tuberculosis cases by
year from 1998, the first year when the estimated case detection
rate exceeded 70% [14], through 2012. We used the UNAIDS
Estimates and Projection Package (EPP) model to estimate the
annual prevalence of HIV infection in the adult population during
this time period [15]. We assumed an HIV prevalence ratio of six
for tuberculosis patients compared to the general population
because this ratio caused the crude estimates for 2006–2012 to be
consistent with estimates from our detailed analysis, and because
this was the average ratio observed across six groups of developing
countries in an analysis of the global burden of tuberculosis
attributable to HIV [16].
Data Availability Statement
All data used in this manuscript represent publically available
information. Annual numbers of reported tuberculosis cases, HIV
test results for tuberculosis patients, and numbers of adults
receiving antiretroviral therapy are available by request from the
Kenya Ministry of Health (P.O. Box 30016, Nairobi, Kenya;
telephone: +254-20-717077; www.health.go.ke). Data from the
2007 and 2012 KAIS have been published [12,13]. Population
estimates are available by request from the Kenya National
Bureau of Statistics (P.O. Box 30266-00100, Nairobi; telephone: +
254-20-317583; www.knbs.or.ke).
Ethics Statement
The project was determined not to be human subjects research
by the U.S. Centers for Disease Control and Prevention (CDC)
and did not require approval by an institutional review board.
Results
Detailed Estimate of Tuberculosis Incidence, by HIV
Status, 2006–2012
The number of new tuberculosis cases reported by year in
Kenya during 2006–2012 is shown in Table 1 and Figure 1. The
proportion of tuberculosis patients with HIV test results increased
from 59.5% in 2006 to 93.9% in 2012 (Table 1). The proportion
of patients with positive HIV test results among those tested
decreased from 51.3% in 2006 to 37.2% in 2012 (Table 1). The
number of patients with positive HIV test results also decreased
during 2007–2012 (Figure 1). Based on the results of KAIS, the
prevalence of HIV infection among adults aged 15–64 years was
estimated to be 7.1% (95% confidence interval [CI]: 6.5–7.7) in
2007 and 5.6% (95% CI: 4.9–6.3) in 2012 [12,13].
Table 1. Number and HIV test results of new tuberculosis patients –Kenya, 2006–2012.
Year New tuberculosis patients Proportion with HIV test result Proportion with positive result among those tested
2006 104,935 59.50% 51.30%
2007 106,261 78.30% 47.10%
2008 99,807 82.60% 44.00%
2009 99,354 87.50% 42.80%
2010 95,604 91.10% 40.30%
2011 93,964 93.20% 38.20%
2012 89,143 93.90% 37.20%
doi:10.1371/journal.pone.0099880.t001
Figure 2. Tuberculosis incidence estimates and antiretroviral therapy uptake among adults – Kenya, 2006–2012. Upper- and lower-
bound estimates of tuberculosis incidence among adults aged 15–64 years with (solid black line) and without (solid grey line) HIV infection, and
proportion of adults aged 15–64 years with HIV infection who were receiving antiretroviral therapy (ART) (dashed black line).
doi:10.1371/journal.pone.0099880.g002
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Figure 2 shows estimated tuberculosis incidence during 2006–
2012 among adults aged 15–64 years, by HIV status. Because of
the substantial proportion of patients in 2006 without HIV test
results available, it is unclear how tuberculosis incidence changed
during 2006–2007. However, during 2007–2012, tuberculosis
incidence declined by 28–44% among adults living with HIV and
by 11–26% among adults without HIV. In 2012, tuberculosis
incidence among adults living with HIV was 1,839–1,936 cases
per 100,000 population, while tuberculosis incidence among adults
without HIV was 231–238 cases per 100,000 population. During
2006–2012, the estimated overall proportion of adults living with
HIV who were receiving antiretroviral therapy increased from 7%
to 37% (Figure 2).
In 2012, 32–34% of tuberculosis cases among adults aged 15–64
years in Kenya were attributable to HIV (Figure 3). However,
because of the large difference between upper- and lower-bound
incidence estimates for the early years of the analysis period, it is
unclear how the population attributable fraction has changed
during 2006–2012.
To assess the robustness of our estimate, we performed
sensitivity analyses to determine how making different assumptions
about the age distribution of tuberculosis patients would change
our results. Rather than assuming a negligible number of
tuberculosis patients over 64 years of age, we assumed 95% of
tuberculosis cases among adults to have occurred in those aged
15–64 years, based on the age distribution of adult tuberculosis
patients in select regions for which disaggregated data were
available. We then tested two assumptions for the age distribution
of positive HIV test results: either that all positive HIV test results
in adults occurred among those aged 15–64 years or that the
proportion of adult tuberculosis patients with positive HIV test
results was the same among those aged 15–64 years as among
those over aged 64 years. Using either set of assumptions changed
our estimates by less than 10%, and overall trends in tuberculosis
incidence during the analysis period remained the same.
Crude Estimate of Tuberculosis Incidence, by HIV Status,
1998–2012
The number of reported tuberculosis cases in Kenya and the
estimated prevalence of HIV infection in adults based on the EPP
model [15] during 1998–2007 are shown in Figure 4A. Crude
estimates of tuberculosis incidence based on an assumed HIV
prevalence ratio of six for tuberculosis patients compared to the
general population are shown in Figure 4B. Among persons living
with HIV, tuberculosis incidence increased during 1998–2004,
remained relatively stable until 2007 at approximately 2,750 cases
per 100,000 population, then declined to 1,962 cases per 100,000
population in 2012. Among persons without HIV, the trend was
similar, but overall incidence was substantially lower, peaking at
approximately 320 cases per 100,000 population during 2005–
2007, and declining to 231 cases per 100,000 population in 2012.
Based on these estimates, the population attributable fraction of
tuberculosis due to HIV declined steadily from 62% in 1998 to
29% in 2007, then remained stable (Figure 4C).
Discussion
Using reported HIV test results among tuberculosis patients and
estimates of HIV prevalence from population-based surveys, we
estimated tuberculosis incidence among adults in Kenya, stratified
by HIV status. Tuberculosis incidence among adults living with
HIV and among adults without HIV both appear to have declined
since 2007. However, despite success in the scale-up of antiret-
roviral therapy in Kenya, tuberculosis incidence among adults
living with HIV in 2012 was still nearly 2,000 per 100,000
population, roughly eight times as high as among adults without
HIV. Furthermore, during 2006–2012, over 30% of new adult
tuberculosis cases were attributable to HIV while the prevalence of
HIV infection in the adult population ranged from 6–7%,
suggesting the disproportionate burden of tuberculosis borne by
persons living with HIV.
With an overall tuberculosis incidence of 272 per 100,000
population in 2012, the annual rate of decline of less than 6%
observed over the past three years in Kenya [1] is insufficient for
the country to achieve the global target of eliminating tuberculosis
as a public health problem by 2050. To accelerate the decline in
tuberculosis incidence, a combination of interventions will be
necessary. Mathematical models suggest that on a global scale,
improving diagnosis and treatment of active disease, the primary
focus of most national tuberculosis programs, could at best bring
about an 8.5-fold decrease in tuberculosis incidence by 2050 [17].
Achieving tuberculosis elimination, defined as an incidence of 1
case per million population, by 2050 will require not only
increasing tuberculosis case detection but also implementing good
measures to prevent tuberculosis, including treatment of latent
infection [17]. In countries with high burdens of HIV, tuberculosis
prevention among persons living with HIV will require providing
both antiretroviral therapy to prevent development of active
disease and tuberculosis preventive therapy to treat latent infection
[17,18].
Antiretroviral therapy has been shown to substantially decrease
tuberculosis incidence in persons living with HIV, particularly
when it is initiated while CD4 counts are still comparatively high
[5,6,19]. Consistent with this effect, we observed that the scale-up
in antiretroviral therapy programs in Kenya coincided with a
more pronounced decline in tuberculosis incidence during 2007–
2012 among adults with HIV than among adults without HIV,
although we cannot conclude causality based on our analysis.
Specific interventions that may have contributed to the decrease in
tuberculosis incidence among persons with HIV during this period
include raising the CD4 threshold for initiation on antiretroviral
therapy and expanding HIV testing services. The CD4 threshold
defining general eligibility for initiation of antiretroviral therapy in
adults was raised from 200 cells/mm3 to 250 cells/mm3 in 2007,
and to 350 cells/mm3 in 2010 [10]. Furthermore, the availability of
Figure 3. Estimates of tuberculosis attributable to HIV among
adults – Kenya, 2006–2012. Upper- and lower-bound estimates of
population attributable fraction of incident tuberculosis attributable to
HIV among adults aged 15–64 years.
doi:10.1371/journal.pone.0099880.g003
Tuberculosis Trends by HIV Status, Kenya 1998–2012
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Figure 4. Crude estimates of tuberculosis incidence among adults with and without HIV infection – Kenya, 1998–2012. Adults are
defined as persons $15 years of age. (A) Reported tuberculosis cases in adults (solid line) and estimated prevalence of HIV infection in the general
adult population (dashed line), (B) estimated tuberculosis incidence among adults with (dashed line) and without (solid line) HIV infection, (C)
estimated population attributable fraction of tuberculosis cases attributable to HIV among adults.
doi:10.1371/journal.pone.0099880.g004
Tuberculosis Trends by HIV Status, Kenya 1998–2012
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HIV testing services was increased from three sites in 1999 to nearly
2,000 sites in 2010, and provider-initiated testing policies were
introduced in addition to existing voluntary testing services [10,20].
However, while the scale-up of antiretroviral therapy programs
in Kenya over the past several years has been impressive, almost
two thirds of adults living with HIV in Kenya were not receiving
antiretroviral therapy in 2012 [13]. Of these, 26% were unaware
of their HIV status, and 66% were aware of their HIV status but
not eligible for antiretroviral therapy [13]. Mathematical modeling
studies based on data from sub-Saharan African countries have
suggested that substantial declines in tuberculosis incidence could
be achieved by initiating antiretroviral therapy as soon as HIV
infection is known, without waiting for a threshold CD4 count to
be reached [21,22]. Thus, further expansion of HIV testing
initiatives and earlier initiation of antiretroviral therapy will be
necessary to realize the full benefit of antiretroviral therapy on
reducing tuberculosis incidence in Kenya.
While continued scale-up of antiretroviral therapy programs is
important, multiple studies have suggested that tuberculosis
incidence among persons on antiretroviral therapy and with high
CD4 counts still exceeds incidence in the HIV-negative population
[23–25]. Therefore, additional interventions will be necessary if
the disparity in tuberculosis incidence between persons with and
without HIV is to be addressed. These include identification of all
persons living with HIV, early initiation of antiretroviral therapy,
routine symptom-based screening for tuberculosis disease, and
provision of tuberculosis preventive therapy to prevent develop-
ment of tuberculosis disease.
World Health Organization guidelines recommend routine
symptom-based screening for tuberculosis among persons living
with HIV and provision of tuberculosis preventive therapy for
persons with a negative symptom screen [26]. In persons with HIV
who have a positive tuberculin skin test result, tuberculosis
preventive therapy can reduce the risk of developing tuberculosis
disease by over 60% [7] and the combination of antiretroviral
therapy and continuous tuberculosis preventive therapy can reduce
tuberculosis incidence by over 90% [8]. While screening for
tuberculosis has been integrated into HIV care in Kenya,
tuberculosis preventive therapy has not yet been widely implement-
ed [10]. To achieve the maximum benefit of Kenya’s integrated
TB/HIV policy, it is important that screening for tuberculosis
among persons living with HIV be rigorous, that every person
meeting criteria for further evaluation be tested with a sensitive
tuberculosis diagnostic test, and that if indicated, preventive therapy
be given to those confirmed not to have tuberculosis.
Although tuberculosis disproportionately affects persons living
with HIV, much transmission of tuberculosis is driven by persons
without HIV, who typically remain contagious for longer periods
of time [27]. Therefore, interventions to decrease tuberculosis
incidence in the general population are necessary to prevent new
infections among persons living with HIV. As delayed diagnosis
leads to prolongation of infectiousness and effective treatment
rapidly attenuates infectiousness [17,28], early diagnosis and
initiation of appropriate treatment are critical to reducing
transmission. Accomplishing both of these goals will require
diagnostic tests more sensitive than sputum-smear microscopy and
increasing early tuberculosis case finding through active case
finding strategies.
Interventions aimed at reducing transmission of HIV may also
have the indirect benefit of reducing tuberculosis incidence. Our
crude analysis suggests that during 1998–2007, the proportion of
tuberculosis cases attributable to HIV declined by roughly 50%,
driven by a decline of similar magnitude in HIV prevalence in the
overall population. Thus, further reductions in HIV transmission
could decrease the pool of vulnerable persons who are at higher
risk of developing tuberculosis, which in turn should decrease new
tuberculosis cases.
Our analysis was subject to several limitations. The proportion
of tuberculosis patients with unknown HIV status, particularly
during early years of the analysis period, prevented us from
making point estimates of incidence. In addition, because
tuberculosis case data were incompletely disaggregated by age,
we assumed a negligible number of tuberculosis patients over 64
years of age to match the age group to which the KAIS estimates
correspond. However, sensitivity analyses suggested that making
different assumptions based on the age distribution of adult
tuberculosis patients in districts where more detailed data were
available would have changed our estimates by less than 10%, and
the same trends would have been observed.
The lack of recorded HIV test results for tuberculosis cases
reported before 2006 forced us to make crude estimates to analyze
trends in tuberculosis incidence before 2006. These crude
estimates relied on the assumption of a constant prevalence ratio
of HIV infection between tuberculosis patients and the general
population when this ratio may in fact have changed over time.
Furthermore, the prevalence of HIV infection used in the crude
estimates came from a mathematical model based on HIV
prevalence data from anonymous serosurveys among pregnant
women attending public antenatal clinics, although the projection
curves for the model were calibrated using national estimates of
HIV prevalence from historical population-based household
surveys [15].
Finally, our model did not take into account changes in
tuberculosis case detection rate or treatment success rate over
time. Although programmatic estimates suggest case detection
rates between 70–85% starting in 1998 [14], inaccuracy in these
estimates would be propagated in our incidence estimates. If case
detection rates in the early part of the analytic period were in fact
lower than estimated, then tuberculosis incidence may have been
even higher during that period, and the decline in incidence
consequently sharper. Treatment success rates were high through-
out the study period (81–88% for new sputum smear-positive cases
[29,30]), so changes in treatment success rate were unlikely to have
affected tuberculosis incidence.
In conclusion, the decline in tuberculosis incidence both among
adults living with HIV and adults without HIV suggests the success
of tuberculosis control efforts in Kenya in recent years and likely
the effect of expanded HIV testing and antiretroviral therapy
programs. However, the persistent high incidence of tuberculosis
among adults living with HIV is cause for concern, given that
tuberculosis remains the leading cause of death in people with
HIV. A concerted effort aimed at decreasing transmission by
controlling tuberculosis in the general population should be
combined with specific interventions among persons living with
HIV to reduce tuberculosis incidence among this population.
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